Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment

AIM: Currently, there is no consensus on the retreatment recommendation of chronic hepatitis B (CHB) patients with viral rebound after cessation of treatment. In the search of reasonable treatment, we compared the efficacy and safety of adefovir (ADV) plus lamivudine (LAM) and LAM alone for the retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhao, Wu, Xiao-Ling, Zeng, Wei-Zheng, Xu, Hui, Zhang, Yong, Qin, Jian-Ping, Jiang, Ming-De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162546/
https://www.ncbi.nlm.nih.gov/pubmed/21816062
http://dx.doi.org/10.1186/1743-422X-8-388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162546/
https://www.ncbi.nlm.nih.gov/pubmed/21816062
http://dx.doi.org/10.1186/1743-422X-8-388

Ejemplares similares